Hara Fumihiro None;
Takenori Inomata Santen Pharmaceutical Co., Ltd.; Code P: Renatech Co., Ltd., InnoJin Inc., Code C (Consultant/Contractor), InnoJin, Inc.; , Code E (Employment), Novartis Pharma KK, Santen Pharmaceutical Co., Ltd., Lion Corporation, SEED Co., Ltd., Johnson & Johnson, Shin Nippon Biomedical Laboratories, Ltd., IBM Japan, Ltd.;, Code F (Financial Support);
Tianxiang Huang Johnson & Johnson., FUKOKU Co., Ltd.;, Code F (Financial Support);
Shokirova Hurramhon None;
Yuichi Okumura InnoJin, Inc.;, Code E (Employment), Johnson & Johnson., FUKOKU Co., Ltd.;, Code F (Financial Support), InnoJin, Inc., Code P (Patent);
Maria Miura None;
Keiichi Fujimoto Johnson & Johnson., FUKOKU Co., Ltd.;, Code F (Financial Support);
Jaemyoung Sung None;
Gaku Ishida None;
Shintaro Nakao Kowa Company. Ltd., Mitsubishi Tanabe Pharma Corporation, Alcon Japan, Ltd., Santen Pharmaceutical Co., Ltd., Machida Endoscope Co., Ltd., Wakamoto Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Senju Pharmaceutical Co., Ltd. Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Hoya Corporation, and Novartis Pharma K.K., Code F (Financial Support)